Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric bempedoic acid PK/PD and safety study in heterozygous familial hypercholesterolemia
NL-OMON53717Phase 2Recruiting
- Sponsor
- Esperion Therapeutics
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bempedoic acid in heterozygous familial hypercholesterolemia (HeFH), sponsored by Esperion Therapeutics. Primary endpoints: Observed trough plasma concentration of ETC-1002 after 8 weeks, Steady-state AUCss of ETC-1002 and 2 more. Started Mar 2023; status: recruiting.
02
Drugs
bempedoic acid
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NL-OMON53717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53717.